Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.
We studied the effects of botulinum A toxin in 12 patients with blepharospasm and 10 patients with oromandibular-cervical dystonia received in a double-blind manner. All blepharospasm patients improved, 71.6% on a clinical rating score, 60.7% by self-assessment, and 38.9% by video-rating; there was no improvement with placebo. The beneficial effects lasted a mean of 12.5 weeks (range, 5 to 28). Only 37.5% of the patients with oromandibular-cervical dystonia improved. Patients with pharyngeal dystonia and spasmodic dysphonia also improved.
D000293:Adolescent; D000328:Adult; D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D001764:Blepharospasm / Q000188:drug therapy; D001905:Botulinum Toxins / Q000627:therapeutic use*; D004311:Double-Blind Method; D004421:Dystonia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008538:Meige Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D014832:Voice Disorders / Q000188:drug therapy
D001905:Botulinum Toxins